Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Targeted Drug Delivery using Magnetic Resonance-guided Focused Ultrasound in Diffuse Intrinsic Pontine Glioma
EF 2023-24
Résumé
Diffuse intrinsic pontine glioma (DIPG) is a tumour that typically occurs in children aged 6 - 7 years old and is the leading cause of brain-tumour-related deaths in childhood. The tumour arises in the brainstem, a crucial part of the brain that controls breathing and heart rate, making it impossible to remove through surgery. Current DIPG treatments involve radiation and chemotherapy but are ultimately ineffective at curing this invariably fatal disease. A main challenge to therapy is the blood-brain barrier (BBB), which protects the brain from external compounds, including chemotherapy. However, recent advances such as Magnetic Resonance-guided Focused Ultrasound (MRgFUS) offers the potential to overcome this problem. MRgFUS uses ultrasound waves focused on the tumour to open the BBB safely and temporarily so drugs can pass through into the tumour tissue. Our lab has successfully delivered a chemotherapy drug to DIPG-bearing mice using MRgFUS, and we will now evaluate other drugs predicted to work in treating DIPG. MRgFUS has also been shown to alter the immune system, but exact changes are unknown in DIPG. Understanding how MRgFUS affects the immune system in DIPG patients can further improve its safety. We aim to assess drug candidates for MRgFUS delivery in DIPG mouse models. We will focus on drugs blocked by the BBB and approved for use in patients. Survival of the mice, tumour size, and amount of drug delivered will be evaluated. We also aim to describe how MRgFUS changes the immune system in DIPG-bearing mice. Immune cell populations will be evaluated following MRgFUS treatment. Overall, this allows us to improve drug treatments for DIPG via MRgFUS delivery and to ensure a safer delivery system by understanding the immune system’s responses to MRgFUS.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506445
Name
Lin Catherine Y
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeted Drug Delivery using Magnetic Resonance-guided Focused Ultrasound in Diffuse Intrinsic Pontine Glioma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chemotherapy; Diffuse Intrinsic Pontine Glioma; Drug Delivery; Drug Discovery; Immune Microenvironment; Immunotherapy; Magnetic Resonance-Guided Focused Ultrasound
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a tumour that typically occurs in children aged 6 - 7 years old and is the leading cause of brain-tumour-related deaths in childhood. The tumour arises in the brainstem, a crucial part of the brain that controls breathing and heart rate, making it impossible to remove through surgery. Current DIPG treatments involve radiation and chemotherapy but are ultimately ineffective at curing this invariably fatal disease. A main challenge to therapy is the blood-brain barrier (BBB), which protects the brain from external compounds, including chemotherapy. However, recent advances such as Magnetic Resonance-guided Focused Ultrasound (MRgFUS) offers the potential to overcome this problem. MRgFUS uses ultrasound waves focused on the tumour to open the BBB safely and temporarily so drugs can pass through into the tumour tissue. Our lab has successfully delivered a chemotherapy drug to DIPG-bearing mice using MRgFUS, and we will now evaluate other drugs predicted to work in treating DIPG. MRgFUS has also been shown to alter the immune system, but exact changes are unknown in DIPG. Understanding how MRgFUS affects the immune system in DIPG patients can further improve its safety. We aim to assess drug candidates for MRgFUS delivery in DIPG mouse models. We will focus on drugs blocked by the BBB and approved for use in patients. Survival of the mice, tumour size, and amount of drug delivered will be evaluated. We also aim to describe how MRgFUS changes the immune system in DIPG-bearing mice. Immune cell populations will be evaluated following MRgFUS treatment. Overall, this allows us to improve drug treatments for DIPG via MRgFUS delivery and to ensure a safer delivery system by understanding the immune system’s responses to MRgFUS.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lin, Catherine Y
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~